标题
Cell death-based treatment of lung adenocarcinoma
作者
关键词
-
出版物
Cell Death & Disease
Volume 9, Issue 2, Pages -
出版商
Springer Nature
发表日期
2018-01-26
DOI
10.1038/s41419-017-0063-y
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC
- (2017) Christian Manegold et al. Journal of Thoracic Oncology
- Lung cancer: current therapies and new targeted treatments
- (2017) Fred R Hirsch et al. LANCET
- Combination immunotherapy: a road map
- (2017) Patrick A. Ott et al. Journal for ImmunoTherapy of Cancer
- Antiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine
- (2017) Samer Tabchi et al. Frontiers in Oncology
- Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC).
- (2017) M. G. Kris et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations
- (2016) Mei Ji et al. CANCER BIOLOGY & THERAPY
- Resistance to receptor tyrosine kinase inhibitors in solid tumors: can we improve the cancer fighting strategy by blocking autophagy?
- (2016) Sanja Aveic et al. Cancer Cell International
- Study Design and Rationale for a Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Selumetinib in Combination With Docetaxel as Second-Line Treatment in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer (SELECT-1)
- (2016) Pasi A. Jänne et al. Clinical Lung Cancer
- Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
- (2016) Scott Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Trends and advances in tumor immunology and lung cancer immunotherapy
- (2016) Mohanad Aldarouish et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Scientific Advances in Lung Cancer 2015
- (2016) Anne S. Tsao et al. Journal of Thoracic Oncology
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial
- (2016) Nasser H. Hanna et al. LUNG CANCER
- Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer
- (2016) Kaichao Feng et al. Science China-Life Sciences
- Lapatinib induces autophagic cell death and differentiation in acute myeloblastic leukemia
- (2016) Huey-Lan Huang et al. OncoTargets and Therapy
- Antiangiogenic Agents and Vascular Disrupting Agents for the Treatment of Lung Cancer: A Review
- (2016) Christelle Clément-Duchêne et al. Journal of Thoracic Oncology
- Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib
- (2015) C. F. Spraggs et al. ANNALS OF ONCOLOGY
- EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB
- (2015) Kailong Lin et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- EGFR-independent autophagy induction with gefitinib and enhancement of its cytotoxic effect by targeting autophagy with clarithromycin in non-small cell lung cancer cells
- (2015) Shohei Sugita et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- 3BA A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial
- (2015) R.A. Stahel et al. EUROPEAN JOURNAL OF CANCER
- Targeted therapies for treatment of non-small cell lung cancer-Recent advances and future perspectives
- (2015) Joan Minguet et al. INTERNATIONAL JOURNAL OF CANCER
- Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition
- (2015) Francesca Megiorni et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Non–Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy
- (2015) David P. Carbone et al. Journal of Thoracic Oncology
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- (2015) Pasi A. Jänne et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of resistance to EGFR tyrosine kinase inhibitors
- (2015) Lihua Huang et al. Acta Pharmaceutica Sinica B
- PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
- (2014) A D'Incecco et al. BRITISH JOURNAL OF CANCER
- Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance
- (2014) Tatsushi Kodama et al. CANCER LETTERS
- New Strategies in Lung Cancer: Translating Immunotherapy into Clinical Practice
- (2014) Patrick M. Forde et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies
- (2014) C. M. Lovly et al. CLINICAL CANCER RESEARCH
- Immuno-oncology Combinations: A Review of Clinical Experience and Future Prospects
- (2014) S. J. Antonia et al. CLINICAL CANCER RESEARCH
- New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape
- (2014) Deepak Mittal et al. CURRENT OPINION IN IMMUNOLOGY
- Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
- (2014) Mark G. Kris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
- (2014) Takashi Seto et al. LANCET ONCOLOGY
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Autophagosome-Mediated EGFR Down-Regulation Induced by the CK2 Inhibitor Enhances the Efficacy of EGFR-TKI on EGFR-Mutant Lung Cancer Cells with Resistance by T790M
- (2014) Kwang Sup So et al. PLoS One
- Inhibition of autophagy significantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells
- (2014) Hang Yuan WORLD JOURNAL OF GASTROENTEROLOGY
- Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma
- (2014) Yang Zhang et al. OncoTargets and Therapy
- The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
- (2014) L. Friboulet et al. Cancer Discovery
- Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells
- (2013) Magali Humbert et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
- (2013) Y. Huang et al. CANCER RESEARCH
- EGFR-TKI Resistance Due to BIM Polymorphism Can Be Circumvented in Combination with HDAC Inhibition
- (2013) T. Nakagawa et al. CANCER RESEARCH
- Caspase-Independent Cell Death Is Involved in the Negative Effect of EGF Receptor Inhibitors on Cisplatin in Non-Small Cell Lung Cancer Cells
- (2013) H. Yamaguchi et al. CLINICAL CANCER RESEARCH
- Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects
- (2013) Giuseppe Bronte et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Novel therapeutic targets in non-small cell lung cancer
- (2013) Muhammad Alamgeer et al. CURRENT OPINION IN PHARMACOLOGY
- Harnessing the Immune System for the Treatment of Non–Small-Cell Lung Cancer
- (2013) Julie R. Brahmer JOURNAL OF CLINICAL ONCOLOGY
- MET As a Possible Target for Non–Small-Cell Lung Cancer
- (2013) Ahad A. Sadiq et al. JOURNAL OF CLINICAL ONCOLOGY
- Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
- (2013) Julien Mazières et al. JOURNAL OF CLINICAL ONCOLOGY
- Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
- (2013) Justin F. Gainor et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib
- (2013) Yiyu Zou et al. Journal of Thoracic Oncology
- Genetics and biomarkers in personalisation of lung cancer treatment
- (2013) Rafael Rosell et al. LANCET
- Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib
- (2013) Alfredo Tartarone et al. LUNG CANCER
- Genetic alterations defining NSCLC subtypes and their therapeutic implications
- (2013) Larissa A. Pikor et al. LUNG CANCER
- BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer
- (2013) B. Kutluk Cenik et al. MOLECULAR CANCER THERAPEUTICS
- Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions
- (2013) J. F. Gainor et al. ONCOLOGIST
- Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer
- (2013) M. J. Niederst et al. Science Signaling
- Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
- (2013) H. Yasuda et al. Science Translational Medicine
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
- (2013) E. A. Akbay et al. Cancer Discovery
- Erlotinib Resistance in Lung Cancer: Current Progress and Future Perspectives
- (2013) Joy Tang et al. Frontiers in Pharmacology
- Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics
- (2013) Giulia M Stella et al. Lancet Respiratory Medicine
- Non-Small-Cell Lung Cancer: Treatment of Late Stage Disease: Chemotherapeutics and New Frontiers
- (2013) Ronald Scheff et al. SEMINARS IN INTERVENTIONAL RADIOLOGY
- Immunogenic Cell Death in Cancer Therapy
- (2012) Guido Kroemer et al. Annual Review of Immunology
- EGFR tyrosine kinase inhibition induces autophagy in cancer cells
- (2012) Christopher Fung et al. CANCER BIOLOGY & THERAPY
- The battle against ALK resistance: successes and setbacks
- (2012) Claudia Voena et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Cancer and Innate Immune System Interactions
- (2012) Yanan Liu et al. JOURNAL OF IMMUNOTHERAPY
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
- (2012) D Ross Camidge et al. LANCET ONCOLOGY
- Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
- (2012) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
- (2012) Zhenfeng Zhang et al. NATURE GENETICS
- Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth
- (2012) C Dudgeon et al. ONCOGENE
- Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
- (2012) K. Ohashi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation
- (2012) Ken Takezawa et al. Cancer Discovery
- A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer
- (2011) M. Reck et al. ANNALS OF ONCOLOGY
- Natural Innate and Adaptive Immunity to Cancer
- (2011) Matthew D. Vesely et al. Annual Review of Immunology
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor-Induced Apoptosis in EML4-ALK-Positive Lung Cancer
- (2011) K. Takezawa et al. CLINICAL CANCER RESEARCH
- The immunological synapse: a cause or consequence of T-cell receptor triggering?
- (2011) Balbino Alarcón et al. IMMUNOLOGY
- Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Richard H. de Boer et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer Immunotherapy Comes of Age
- (2011) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunotherapy for Non-small Cell Lung Cancer: Novel Approaches to Improve Patient Outcome
- (2011) Frances A. Shepherd et al. Journal of Thoracic Oncology
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
- (2011) William D. Travis et al. Journal of Thoracic Oncology
- New driver mutations in non-small-cell lung cancer
- (2011) William Pao et al. LANCET ONCOLOGY
- FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR
- (2011) Trever G. Bivona et al. NATURE
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Normalization of the Vasculature for Treatment of Cancer and Other Diseases
- (2011) Shom Goel et al. PHYSIOLOGICAL REVIEWS
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines
- (2010) Hua Cheng et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers
- (2010) K. N. Kodumudi et al. CLINICAL CANCER RESEARCH
- Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
- (2010) Gang Niu et al. CURRENT DRUG TARGETS
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The paradox of autophagy and its implication in cancer etiology and therapy
- (2009) Avital Eisenberg-Lerner et al. APOPTOSIS
- EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases
- (2009) K. Schmid et al. CLINICAL CANCER RESEARCH
- Apoptosis and autophagy: Targeting autophagy signalling in cancer cells -‘trick or treats’?
- (2009) Elisabeth A. Corcelle et al. FEBS Journal
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- (2009) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy
- (2009) Akira Inoue et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study
- (2009) Glenwood D. Goss et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer
- (2009) David Jackman et al. JOURNAL OF CLINICAL ONCOLOGY
- Small Cell Lung Cancer
- (2009) Taimur Sher et al. MAYO CLINIC PROCEEDINGS
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
- (2009) A F Gazdar ONCOGENE
- BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
- (2008) F. Hilberg et al. CANCER RESEARCH
- Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy
- (2008) Giuseppe Giaccone et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- EGFR Antagonists in Cancer Treatment
- (2008) Fortunato Ciardiello et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now